The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis
Author(s) -
ChiaHsin Chan,
ChienFeng Li,
Wei-Lei Yang,
Yuan Gao,
Szu-Wei Lee,
Zizhen Feng,
Hsuan-Ying Huang,
Kelvin K. Tsai,
Leo G. Flores,
Yiping Shao,
John D. Hazle,
Dihua Yu,
Wenyi Wei,
Dos D. Sarbassov,
MienChie Hung,
Keiichi I. Nakayama,
HuiKuan Lin
Publication year - 2012
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2012.02.065
Subject(s) - protein kinase b , ubiquitin ligase , biology , cancer research , skp2 , erbb , carcinogenesis , akt2 , ubiquitin , signal transduction , microbiology and biotechnology , cancer , akt1 , biochemistry , genetics , gene
Akt kinase plays a central role in cell growth, metabolism, and tumorigenesis. The TRAF6 E3 ligase orchestrates IGF-1-mediated Akt ubiquitination and activation. Here, we show that Akt ubiquitination is also induced by activation of ErbB receptors; unexpectedly, and in contrast to IGF-1 induced activation, the Skp2 SCF complex, not TRAF6, is a critical E3 ligase for ErbB-receptor-mediated Akt ubiquitination and membrane recruitment in response to EGF. Skp2 deficiency impairs Akt activation, Glut1 expression, glucose uptake and glycolysis, and breast cancer progression in various tumor models. Moreover, Skp2 overexpression correlates with Akt activation and breast cancer metastasis and serves as a marker for poor prognosis in Her2-positive patients. Finally, Skp2 silencing sensitizes Her2-overexpressing tumors to Herceptin treatment. Our study suggests that distinct E3 ligases are utilized by diverse growth factors for Akt activation and that targeting glycolysis sensitizes Her2-positive tumors to Herceptin treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom